SCHEMBL6691749

SCHEMBL6691749

O=C(O)NCCc1cc(Cl)cc(Cl)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 5/20 0.58
ALDH1A1 P00352 4/20 0.49
KMT2A Q03164 3/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
MEN1 O00255 2/20 0.49
HPGD P15428 1/20 0.49
TAAR1 Q96RJ0 3/20 0.46
PLAAT3 P53816 2/20 0.45
PLAAT5 Q96KN8 2/20 0.45
PLAAT2 Q9NWW9 2/20 0.45
PLAAT4 Q9UL19 2/20 0.45
LMNA P02545 2/20 0.45
KDM4E B2RXH2 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
GLA P06280 1/20 0.44
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
MAPT P10636 2/20 0.43
CYP1A2 P05177 1/20 0.42
CYP2D6 P10635 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23199613 0.91 CNR1 (0.51) CNR1ALDH1A1KMT2ASMN1; SMN2MEN1
SCHEMBL31579654 0.82 CNR1 (0.57) CNR1ALDH1A1KMT2ASMN1; SMN2MEN1
SCHEMBL4525519 0.82 ALDH1A1 (0.72) CNR1ALDH1A1KMT2ASMN1; SMN2MEN1
SCHEMBL28067780 0.81 CNR1 (0.49) CNR1ALDH1A1KMT2ASMN1; SMN2MEN1
SCHEMBL16822086 0.80 HCAR2 (0.44) CNR1ALDH1A1KMT2ASMN1; SMN2MEN1
SCHEMBL4582082 0.80 TAAR1 (0.65) CNR1ALDH1A1SMN1; SMN2TAAR1PLAAT3
SCHEMBL17513300 0.79 MARS1 (0.48) CNR1ALDH1A1KMT2AMEN1FABP4
SCHEMBL11121464 0.79 TACR1 (0.56) CNR1KMT2AMEN1CYP1A2CYP2D6
SCHEMBL5705198 0.79 GLA (0.57) CNR1KMT2ASMN1; SMN2TAAR1LMNA
SCHEMBL21332641 0.79 EPHX2 (0.58) CNR1ALDH1A1SMN1; SMN2TAAR1PLAAT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1419538-A Integrated process for the preparation of aromatic isocyanates and procedures for effecting the relative intermediate phases ENICHEM SPA (IT) 2003-05-21 CN claimed
US-20040181094-A1 Transition metal oxo complexes as catalysts of synthetic processes involving alkyne reactants REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE 2004-09-16 US disclosed
CN-1419538-A Integrated process for the preparation of aromatic isocyanates and procedures for effecting the relative intermediate phases ENICHEM SPA (IT) 2003-05-21 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040181094-A1 Transition metal oxo complexes as catalysts of synthetic processes involving alkyne reactants POLR1G, PYM1, APEX1 CNR1 1784/4885ALDH1A1 3099/4885KMT2A 1209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.